Instil Bio (TIL) AI Stock Analysis

• Market Cap: $143.86M
• Dividend Yield: N/A
• Average Volume (3M): 437.79K
• Price to Earnings (P/E): ―
• Beta (1Y): 4.58
• Revenue Growth: N/A
• EPS Growth: 52.54%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -4.32
• Shares Outstanding: 6,559,927
• 10 Day Avg. Volume: 308,020
• 30 Day Avg. Volume: 437,791
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.22
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.31
• Enterprise Value/Market Cap: 0.82
• Enterprise Value/Revenue: 5.12
• Enterprise Value/Gross Profit: -59.10
• Enterprise Value/Ebitda: -0.34
• 1Y Price Target: $125.00
• Price Target Upside: 470.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 34 Underperform
• Price Target: ―

Instil Bio's stock faces considerable challenges primarily due to severe financial instability, as evidenced by the absence of revenue and ongoing losses. The technical analysis indicates a bearish trend, with the stock significantly underperforming compared to its moving averages. Additionally, the company’s valuation metrics, including a negative P/E ratio and no dividend yield, further underscore the high risk associated with this investment. These factors combine to give Instil Bio a low overall stock score.

Positive Factors

Acquisition Potential

The rising values of these transactions should provide further confidence that the highly positive clinical impact of these PD-1/L1 x VEGF bispecifics is real and highlights potential for Instil Bio to become an acquisition target of interest, given encouraging data generated to date.

Financial Outlook

The 12-month price target for Instil Bio has been increased to $125 from the previous $105, indicating a stronger financial outlook.

Market Potential

Upon the unveiling of the full HARMONi-2 dataset, read-through to Instil Bio led to a nearly 500% increase in the TIL stock price.

Negative Factors

Clinical Development Delays

U.S. clinical development pushed out to YE25. For the second time, Instil has pushed out the initiation of the U.S. trial evaluating AXN-2510 in combo with chemo as a treatment for 1L NSCLC to YE25.

Competition

Instil appears to be losing ground to multiple new assets that are expected to submit INDs by YE25.

Financial Performance

Instil reported a 1Q25 net loss of $4.32 vs. our estimated net loss of $2.23 per share.

Instil Bio Business Overview & Revenue Model

Company Description

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

How the Company Makes Money

Instil Bio generates revenue primarily through the development and commercialization of its TIL-based therapies. The company may enter into strategic partnerships and collaborations with other biotech firms, research institutions, or pharmaceutical companies to co-develop and commercialize therapies, which can include upfront payments, milestone payments, and royalties based on sales. Additionally, as its products move through clinical trials and, if successful, receive regulatory approval, revenue can be generated from the sale of these therapies to healthcare providers and institutions treating cancer patients. Other potential revenue streams could include licensing its technology to other companies in the biotechnology and pharmaceutical sectors.

Instil Bio Financial Statement Overview

Summary

Instil Bio is facing significant financial challenges, characterized by no revenue generation, ongoing losses, and negative cash flows. While the balance sheet shows liquidity strength, the reliance on equity financing poses dilution risks. The company's financial health is precarious, requiring substantial strategic shifts to achieve sustainable operations.

Income Statement

Instil Bio has reported no revenue for several consecutive years, indicating significant challenges in monetizing its technology or products. The absence of revenue coupled with consistent and substantial net losses highlight severe profitability issues. Although there is a reduction in net loss from the prior year, the company still faces major financial hurdles.

Balance Sheet

The company maintains a reasonable cash position with cash and short-term investments of $113 million, providing some liquidity. However, the debt-to-equity ratio is low due to minimal debt, which is a positive. The equity ratio indicates a strong reliance on equity financing, suggesting potential dilution risks for investors. Overall, the balance sheet shows liquidity strength but significant equity erosion over time.

Cash Flow

Operating cash flow remains deeply negative, reflecting ongoing operational losses. There is a notable decrease in negative free cash flow from the previous year, indicating some improvement in cash management. However, consistent negative cash flow from operations poses a significant risk to financial sustainability without additional financing.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	138.00K
Gross Profit	0.00	-4.76M	-5.99M	-2.75M	138.00K
EBITDA	-61.53M	-146.12M	-217.38M	-154.00M	-33.39M
Net Income	-74.14M	-156.09M	-223.18M	-156.79M	-37.74M
Balance Sheet
Total Assets	263.57M	325.63M	482.13M	609.98M	319.01M
Cash, Cash Equivalents and Short-Term Investments	113.31M	150.36M	260.92M	454.10M	241.71M
Total Debt	86.89M	86.05M	79.90M	0.00	0.00
Total Liabilities	94.13M	99.80M	118.52M	54.78M	358.61M
Stockholders Equity	169.44M	225.83M	363.61M	555.20M	-39.60M
Cash Flow
Free Cash Flow	-55.70M	-102.69M	-264.75M	-179.97M	-80.43M
Operating Cash Flow	-55.70M	-82.03M	-180.16M	-122.14M	-29.62M
Investing Cash Flow	53.97M	41.13M	114.54M	-474.40M	-51.12M
Financing Cash Flow	1.75M	8.08M	71.89M	393.16M	313.05M

Instil Bio Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 21.93
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TIL, the sentiment is Neutral. The current price of 21.93 is below the 20-day moving average (MA) of 29.63, below the 50-day MA of 22.47, and below the 200-day MA of 26.74, indicating a neutral trend. The MACD of -0.49 indicates Positive momentum. The RSI at 45.83 is Neutral, neither overbought nor oversold. The STOCH value of 13.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TIL.

Instil Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.55B	0.39	-61.90%	2.32%	17.14%	1.55%
ZURA	43 Neutral	$64.97M	―	-62.34%	―	―	86.65%
NKTX	39 Underperform	$117.79M	―	-26.10%	―	―	30.76%
TNYA	36 Underperform	$98.09M	―	-76.21%	―	―	23.55%
TIL	34 Underperform	$143.86M	―	-44.50%	―	―	52.54%
XBIT		$96.65M	―	-20.53%	―	―	―
KYTX	36 Underperform	$119.72M	―	-49.72%	―	―	―

Instil Bio Corporate Events

Instil Bio Reports 2024 Financial Results and Outlook

Instil Bio reported its fourth quarter and full year 2024 financial results, highlighting a decrease in cash and marketable securities compared to the previous year. The company anticipates significant clinical developments in 2025, including data updates and trial initiations for its lead asset AXN-2510/IMM2510 in collaboration with ImmuneOnco, which could impact its operations and industry positioning.